18 results
425
APGN
Apexigen Inc
11 Aug 23
Business combination disclosure
7:26am
) posters describing the PYX-106-101 and PYX-201-101 Phase 1 clinical trials were accepted for presentation at the Society for the Immunotherapy of Cancer
8-K
EX-99.1
PYXS
Pyxis Oncology Inc
11 Aug 23
Pyxis Oncology Reports Financial Results for Second-Quarter 2023
7:25am
were accepted for presentation at the Society for the Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held November 1-5, 2023, in San Diego
424B3
PYXS
Pyxis Oncology Inc
30 Jun 23
Prospectus supplement
4:05pm
of the originally planned 32 patients in January 2023. In June 2023, data from the APX005M-009 Trial were presented at the American Society of Clinical
S-4/A
PYXS
Pyxis Oncology Inc
29 Jun 23
Registration of securities issued in business combination transactions (amended)
4:09pm
the APX005M-009 Trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting that showed that patients with dedifferentiated
S-4
PYXS
Pyxis Oncology Inc
8 Jun 23
Registration of securities issued in business combination transactions
8:03am
Trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting that showed that patients with dedifferentiated liposarcoma
425
EX-99.1
0hqm1c9 qlg952
24 May 23
Business combination disclosure
4:55pm
8-K
EX-99.1
u8hfz9v3bpojlz f5ob
24 May 23
Regulation FD Disclosure
4:53pm
425
il2ivi
24 May 23
Business combination disclosure
7:05am
425
43pngto7goql 276s
24 May 23
Business combination disclosure
7:03am
8-K
EX-99.1
osgc 0w4z
24 May 23
Pyxis Oncology to Acquire Apexigen
6:59am
10-K
rl525c r4l13bzz9p
29 Mar 22
Annual report
7:36am
424B4
yhzvxp xin2
8 Oct 21
Prospectus supplement with pricing info
5:00pm
S-1
twn00
17 Sep 21
IPO registration
5:00pm
DRS/A
mj1maab75lr
10 Sep 21
Draft registration statement (amended)
12:00am
DRS/A
ztyt r40e14
4 Aug 21
Draft registration statement (amended)
12:00am
DRS
6w1zet gb
21 Jun 21
Draft registration statement
12:00am
- Prev
- 1
- Next